New hope for advanced tumors? first human trial of LM-350 begins
NCT ID NCT07112222
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 38 times
Summary
This early-phase trial is testing an experimental drug called LM-350 in about 80 people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, to find a safe dose and check for side effects; second, to see if the drug can shrink tumors. Participants receive LM-350 by IV every three weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
Contact
-
Cancer Care Wollongong Pty Limited
RECRUITINGWollongong, New South Wales, Australia
Contact
-
Cancer Research SA
RECRUITINGAdelaide, South Australia, Australia
Contact
-
Peninsula and South Eastern Haematology and Oncology Group
RECRUITINGFrankston, Victoria, Australia
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LM-350 (an experimental drug given by IV every 3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early first-in-human trial with only 80 participants, so the drug may not prove safe or effective. Side effects are unknown and could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.